Gossamer Bio

The story of Gossamer Bio is one of seasoned expertise and a focused mission to tackle some of the most challenging diseases. Born from the minds of the former executive team of Receptos, a company successfully acquired by Celgene, Gossamer Bio embarked on its journey in 2015. The name itself, 'Gossamer,' was chosen to symbolize the delicate yet vital connections that bind relationships in life, a principle the company extends to its engagement with patients, employees, shareholders, and partners. This philosophy of interconnectedness and purpose has been the thread weaving through its evolution from a promising startup to a publicly-traded, clinical-stage biopharmaceutical powerhouse.

Initially setting its sights on the broad and complex fields of immunology, inflammation, and oncology, Gossamer Bio strategically leveraged an environment rich with in-licensing opportunities. This approach allowed them to build a diverse pipeline of novel and differentiated therapeutic candidates aimed at addressing significant unmet medical needs. Over the years, the company has honed its focus, dedicating its considerable resources and expertise to the development of its lead investigational product, seralutinib. This therapy is at the forefront of the fight against pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), rare and life-threatening conditions. Through rigorous clinical trials and strategic collaborations, such as a significant global partnership with Chiesi Group, Gossamer Bio is not just developing a drug; it is striving to become an industry leader and, most importantly, to profoundly enhance the lives of patients suffering from these debilitating pulmonary diseases. The journey continues, driven by a culture of scientific rigor, collaboration, and an unwavering commitment to the patient communities it serves.